Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia

Neural Regeneration Research

Volumn 8, Issue 22, 2013, Pages 2050-2059

  Ma, Xing Rong ^a   Sun, Zhi Kun ^b   Liu, Yan Ru ^a   Jia, Yan Jie ^a   Zhang, Bo Ai ^a   Zhang, Jie Wen ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Bilateral common carotid artery occlusion; Cognitive function; Learning and memory; Malonyldialdehyde; Neural regeneration; Neuroregeneration; Oxidative stress; Resveratrol; Superoxide dismutase; Traditional Chinese medicine; Vascular dementia

Indexed keywords

GLUTATHIONE; MALONALDEHYDE; RESVERATROL; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CAROTID ARTERY OBSTRUCTION; COGNITION; COLORIMETRY; CONTROLLED STUDY; EXPERIENTIAL LEARNING; FORCED SWIMMING TEST; HIPPOCAMPUS; MAZE TEST; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; QUANTITATIVE ANALYSIS; RANDOMIZATION; RAT; FEMALE; LEARNING; MALE; MEMORY; MORRIS WATER MAZE TEST; RANDOMIZED CONTROLLED TRIAL;

EID: 84886703858     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2013.22.004     Document Type: Article

References (68)

1. Rockwood K, Wentzel C, Hachinski V, et al. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology. 2000;54(2):447-451.
2. Levine DA, Langa KM. Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neu-rotherapeutics. 2011;8(3):361-373.
3. McVeigh C, Passmore P. Vascular dementia: prevention and treatment. Clin Interv Aging. 2006;1(3):229-235.
4. Román GC. Vascular dementia may be the most common form of dementia in the elderly. J Neurol Sci. 2002;203-204:7-10.
5. Villaflores OB, Chen YJ, Chen CP, et al. Curcuminoids and resveratrol as anti-Alzheimer agents. Taiwan J Obstet Gynecol. 2012;51(4):515-525.
6. Takaoka M. Resveratrol, a new phenolic compound from Veratrum grandiflorum. Nippon Kagaku Kaishi. 1939;60: 1090-1100.
7. Floreani M, Napoli E, Quintieri L, et al. Oral administration of trans-resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects iso-lated atria from menadione toxicity. Life Sci. 2003;72(24): 2741-2750.
8. Wood LG, Wark PA, Garg ML. Antioxidant and an-ti-inflammatory effects of resveratrol in airway disease. Antioxid Redox Signal. 2010;13(10):1535-1548.
9. Chang CC, Chang CY, Huang JP, et al. Effect of resvera-trol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats. Chin J Physiol. 2012;55(3):192-201.
10. Spanier G, Xu H, Xia N, et al. Resveratrol reduces endo-thelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione perox-idase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol. 2009;60 Suppl 4:111-116.
11. Orsu P, Murthy BV, Akula A. Cerebroprotective potential of resveratrol through anti-oxidant and anti-inflammatory mechanisms in rats. J Neural Transm. in press.
12. Athar M, Back JH, Kopelovich L, et al. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys. 2009;486(2):95-102.
13. Sebai H, Sani M, Aouani E, et al. Cardioprotective effect of resveratrol on lipopolysaccharide-induced oxidative stress in rat. Drug Chem Toxicol. 2011;34(2):146-150.
14. Wu JM, Hsieh TC. Resveratrol: a cardioprotective sub-stance. Ann N Y Acad Sci. 2011;1215:16-21.
15. Cui J, Sun R, Yu Y, et al. Antiproliferative effect of resve-ratrol in pancreatic cancer cells. Phytother Res. 2010; 24(11):1637-1644.
16. Richard T, Pawlus AD, Iglésias ML, et al. Neuroprotective properties of resveratrol and derivatives. Ann N Y Acad Sci. 2011;1215:103-108.
17. Yashiro T, Nanmoku M, Shimizu M, et al. Resveratrol increases the expression and activity of the low density lipoprotein receptor in hepatocytes by the proteolytic ac-tivation of the sterol regulatory element-binding proteins. Atherosclerosis. 2012;220(2):369-374.
18. Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventós RM, et al. High urinary levels of resveratrol metabolites are as-sociated with a reduction in the prevalence of cardiovas-cular risk factors in high-risk patients. Pharmacol Res. 2012;65(6):615-620.
19. Simão F, Matté A, Breier AC, et al. Resveratrol prevents global cerebral ischemia-induced decrease in lipid content. Neurol Res. 2013;35(1):59-64.
20. Li Z, Pang L, Fang F, et al. Resveratrol attenuates brain dam-age in a rat model of focal cerebral ischemia via up- regulation of hippocampal Bcl-2. Brain Res. 2012;1450:116-124.
21. Wang Q, Yu S, Simonyi A, et al. Resveratrol protects against neurotoxicity induced by kainic acid. Neurochem Res. 2004;29(11):2105-2112.
22. Pasinetti GM, Wang J, Marambaud P, et al. Neuroprotective and metabolic effects of resveratrol: therapeutic im-plications for Huntington's disease and other neurodege-nerative disorders. Exp Neurol. 2011; 232(1):1-6.
23. Maher P, Dargusch R, Bodai L, et al. ERK activation by the polyphenols fisetin and resveratrol provides neuro-protection in multiple models of Huntington's disease. Hum Mol Genet. 2011;20(2):261-270.
24. Khan MM, Ahmad A, Ishrat T, et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and do-pamine depletion in rat model of Parkinson's disease. Brain Res. 2010;1328:139-151.
25. Jin F, Wu Q, Lu YF, et al. Neuroprotective effect of resve-ratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol. 2008;600(1-3):78-82.
26. Li F, Gong Q, Dong H, et al. Resveratrol, a neuroprotec-tive supplement for Alzheimer's disease. Curr Pharm Des. 2012;18(1):27-33.
27. Vingtdeux V, Dreses-Werringloer U, Zhao H, et al. The-rapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci. 2008;9 Suppl 2:S6.
28. Karuppagounder SS, Pinto JT, Xu H, et al. Dietary sup-plementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int. 2009;54(2):111-118.
29. Jellinger KA. The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol. 2007;113(4): 349-388.
30. Ni J, Ohta H, Matsumoto K, et al. Progressive cognitive impairment following chronic cerebral hypoperfusion in-duced by permanent occlusion of bilateral carotid arteries in rats. Brain Res. 1994;653(1-2):231-236.
31. Kim SK, Cho KO, Kim SY. White matter damage and hippocampal neurodegeneration induced by permanent bilateral occlusion of common carotid artery in the rat: comparison between Wistar and Sprague-Dawley strain. Korean J Physiol Pharmacol. 2008;12(3):89-94.
32. Cechetti F, Worm PV, Pereira LO, et al. The modified 2VO ischemia protocol causes cognitive impairment similar to that induced by the standard method, but with a better survival rate. Braz J Med Biol Res. 2010;43(12):1178-1183.
33. Stasiak A, Mussur M, Unzeta M, et al. The central hista-mine level in rat model of vascular dementia. J Physiol Pharmacol. 2011;62(5):549-558.
34. Gong X, Ma M, Fan X, et al. Down-regulation of IGF-1/IGF-1R in hippocampus of rats with vascular de-mentia. Neurosci Lett. 2012;513(1):20-24.
35. Padurariu M, Ciobica A, Dobrin I, et al. Evaluation of an-tioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett. 2010;479(3):317-320.
36. Greilberger J, Koidl C, Greilberger M, et al. Malondialde-hyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alz-heimer's disease. Free Radic Res. 2008;42(7):633-638.
37. Yang LJ, You YH. Test method of cell in jury induced by oxidative stress. Yixue Zongshu. 2010;16(6):924-927.
38. Monostori P, Wittmann G, Karg E, et al. Determination of glutathione and glutathione disulfide in biological samples: an in-depth review. J Chromatogr B Analyt Technol Bio-med Life Sci. 2009;877(28):3331-3346.
39. Wang J, Zhang HY, Tang XC. Cholinergic deficiency in-volved in vascular dementia: possible mechanism and strategy of treatment. Acta Pharmacol Sin. 2009;30(7): 879-888.
40. Bennett S, Grant MM, Aldred S. Oxidative stress in vas-cular dementia and Alzheimer's disease: a common pa-thology. J Alzheimers Dis. 2009;17(2):245-257.
41. Wassmann S, Wassmann K, Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension. 2004;44(4):381-386.
42. Faraci FM. Reactive oxygen species: influence on cere-bral vascular tone. J Appl Physiol. 2006;100(2):739-743.
43. Faraci FM. Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol. 2011;300(5):H1566-1582.
44. de la Lastra CA, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implica-tions. Biochem Soc Trans. 2007;35(Pt 5):1156-1160.
45. Agarwal B, Campen MJ, Channell MM, et al. Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene expression in vascular en-dothelium. Int J Cardiol. 2012. pii:S0167-5273(12)01133-3.
46. Novaes RD, Peluzio Mdo C, Maldonado IR. Resveratrol causes antiatherogenic effects in an animal model of atherosclerosis. Arq Bras Cardiol. 2012;98(6):571-572.
47. Back JH, Zhu Y, Calabro A, et al. Resveratrol-mediated downregulation of Rictor attenuates autophagic process and suppresses UV-induced skin carcinogenesis. Photo-chem Photobiol. 2012;88(5):1165-1172.
48. Matos RS, Baroncini LA, Précoma LB, et al. Resveratrol causes antiatherogenic effects in an animal model of atherosclerosis. Arq Bras Cardiol. 2012;98(2):136-142.
49. Xu Q, Si LY. Resveratrol role in cardiovascular and me-tabolic health and potential mechanisms of action. Nutr Res. 2012;32(9):648-658.
50. Simão F, Matté A, Pagnussat AS, et al. Resveratrol pre-vents CA1 neurons against ischemic injury by parallel modulation of both GSK-3β and CREB through PI3-K/Akt pathways. Eur J Neurosci. 2012;36(7):2899-2905.
51. Gupta YK, Briyal S, Chaudhary G. Protective effect of trans-resveratrol against kainic acid-induced seizures and oxidative stress in rats. Pharmacol Biochem Behav. 2002; 71(1-2):245-249.
52. Wu Z, Xu Q, Zhang L, et al. Protective effect of resveratrol against kainate-induced temporal lobe epilepsy in rats. Neurochem Res. 2009;34(8):1393-1400.
53. Ho DJ, Calingasan NY, Wille E, et al. Resveratrol protects against peripheral deficits in a mouse model of Hunting-ton's disease. Exp Neurol. 2010;225(1):74-84.
54. Lu KT, Ko MC, Chen BY, et al. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J Agric Food Chem. 2008;56(16): 6910-6913.
55. Albani D, Polito L, Batelli S, et al. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amylo-id-beta (1-42) peptide. J Neurochem. 2009;110(5):1445-1456.
56. Zhang F, Shi JS, Zhou H, et al. Resveratrol protects do-pamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol. 2010;78(3):466-477.
57. Bournival J, Quessy P, Martinoli MG. Protective effects of resveratrol and quercetin against MPP+-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol. 2009;29(8): 1169-1180.
58. Kumar A, Naidu PS, Seghal N, et al. Neuroprotective effects of resveratrol against intracerebroventricular col-chicine-induced cognitive impairment and oxidative stress in rats. Pharmacology. 2007;79(1):17-26.
59. Mishra R, Sellin D, Radovan D, et al. Inhibiting islet amy-loid polypeptide fibril formation by the red wine compound resveratrol. Chembiochem. 2009;10(3):445-449.
60. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem. 2005;280(45):37377-37382.
61. Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alz-heimer's disease and amyotrophic lateral sclerosis. EM-BO J. 2007;26(13):3169-3179.
62. Ciobica A, Padurariu M, Dobrin I, et al. Oxidative stress in schizophrenia - focusing on the main markers. Psychiatr Danub. 2011;23(3):237-245.
63. Takahashi M. Oxidative stress and redox regulation on in vitro development of mammalian embryos. J Reprod Dev. 2012;58(1):1-9.
64. The Ministry of Science and Technology of the People's Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.
65. Su D, Zhao Y, Xu H, et al. Isoflurane exposure during mid-adulthood attenuates age-related spatial memory impairment in APP/PS1 transgenic mice. PLoS One. 2012;7(11):e50172.
66. Huang WH, Li YD, Lin YF, et al. Effects of leukemia inhi-bitory factor and basic fibroblast growth factor on free radicals and endogenous stem cell proliferation in a mouse model of cerebral infarction. Neural Regen Res. 2012;7(19):1469-1474.
67. Zheng SZ, Song L, Lu L, et al. Granulocyte colony- sti-mulating factor increases extracellular glutamic acid up-take and suppresses free radicals in an experimental model of amyotrophic lateral sclerosis. Neural Regen Res. 2011;6(2):107-111.
68. Winerdal M, Winerdal ME, Kinn J, et al. Long lasting local and systemic inflammation after cerebral hypoxic ische-mia in newborn mice. PLoS One. 2012;7(5):e36422.